Start shopping and find your next favourite medicine.
Browse Catalog
Mounjaro 2.5 mg Injection contains tirzepatide, a once-weekly dual GIP and GLP-1 receptor agonist used for type 2 diabetes and weight management. It helps regulate blood sugar, reduce appetite, and prepare patients for higher maintenance doses. Used under medical supervision.
Mounjaro is the brand name for tirzepatide, one of the most significant advances in diabetes and obesity medicine in recent years.
Unlike older medications that target a single hormone pathway, tirzepatide activates both GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors.
That distinction matters.
By working through two complementary metabolic pathways, Mounjaro helps the body regulate blood sugar more efficiently while simultaneously reducing hunger signals that drive overeating.
The 2.5 mg dose is not considered a full therapeutic dose. It is the starting point designed to allow the body to adapt before treatment is gradually increased.
Many patients focus on the higher doses because that is where most of the weight-loss headlines come from.
The reality is that treatment success often begins with the starter dose.
Tirzepatide can cause nausea, fullness, bloating, and digestive changes when introduced too aggressively. The 2.5 mg dose allows the body to adapt gradually, improving long-term adherence and reducing the likelihood of discontinuation.
Think of 2.5 mg as the foundation rather than the destination.
Patients who tolerate the starter dose generally progress to higher maintenance doses based on their physician’s recommendations.
Tirzepatide helps regulate multiple aspects of metabolism:
Unlike semaglutide-based medications that target only GLP-1 receptors, tirzepatide activates both GIP and GLP-1 receptors, creating a broader metabolic effect.
Mounjaro is commonly prescribed for:
It is not intended for type 1 diabetes.
| Condition | Potential Benefit |
|---|---|
| Type 2 Diabetes | Improves glycemic control |
| Elevated HbA1c | Helps achieve treatment targets |
| Obesity | Supports meaningful weight reduction |
| Insulin Resistance | Improves metabolic function |
| Metabolic Syndrome | Assists with weight and glucose management |
Patients often compare Mounjaro with Ozempic® because both are injectable treatments used for diabetes and weight management.
The difference is mechanism.
Ozempic contains semaglutide and targets GLP-1 receptors only.
Mounjaro contains tirzepatide and targets both GIP and GLP-1 receptors.
This dual-action approach is one reason many specialists consider tirzepatide one of the most important developments in metabolic medicine over the past decade.
| Strength | Purpose |
|---|---|
| 2.5 mg | Treatment initiation |
| 5 mg | Early maintenance dose |
| 7.5 mg | Dose escalation |
| 10 mg | Intermediate maintenance |
| 12.5 mg | Advanced titration |
| 15 mg | Maximum maintenance dose |
Dose escalation should only occur under medical supervision.
| Attribute | Details |
|---|---|
| Generic Name | Tirzepatide |
| Brand Name | Mounjaro® |
| Drug Class | Dual GIP & GLP-1 Receptor Agonist |
| Dosage Form | Injection Vial |
| Route of Administration | Subcutaneous Injection |
| Dosing Frequency | Once Weekly |
| Used For | Type 2 Diabetes, Weight Management |
The 2.5 mg dose is primarily a starter dose. Some patients begin losing weight at this stage, but greater weight-loss effects are typically observed after dose escalation.
The lower starting dose helps reduce nausea, vomiting, and digestive side effects while allowing the body to adapt gradually.
Most treatment plans use 2.5 mg for approximately four weeks before increasing to a maintenance dose, although individual schedules may vary.
They are different medications. Mounjaro activates both GIP and GLP-1 receptors, while Ozempic targets only GLP-1 receptors.
Mounjaro is administered once weekly on the same day each week.
Blood sugar improvements often begin within the first few weeks of treatment, although individual responses vary.
Answer: Yes. International shipping is available to many countries, subject to local regulations and product availability.
Answer: Depending on availability, original branded Mounjaro® manufactured by Eli Lilly may be supplied.
Answer: Products are supplied in manufacturer-sealed pharmaceutical packaging and packed securely for international delivery.
Answer: Verify manufacturer information, batch number, expiry date, and original packaging upon receipt.
| Attribute | Details |
|---|---|
| Generic Name | Tirzepatide |
| Brand Name | Mounjaro® |
| Strength | 2.5 mg |
| Dosage Form | Injection Vial |
| Administration | Subcutaneous |
| Frequency | Once Weekly |
| Therapeutic Area | Type 2 Diabetes & Weight Management |
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
| 5 star | 0% | |
| 4 star | 100% | |
| 3 star | 0% | |
| 2 star | 0% | |
| 1 star | 0% |
Good communication and fast responses